There’s one more published case of compassionate usage of WCK 5222 on a patient with skull base osteomyelitis this week (very hard to treat)
DOC-20240228-WA0030…pdf (999.2 KB)
The microbe found was XDR pseudomonas aeruginosa (NDM-MBL producing). The failed treatments include polymyxin B and fosfomycin. Drugs considered include Cefiderocol (CFD), Ceftazidime-Avibactam + Aztreonam (AVI + AZT), Cefepime-Taniborbactam (FEP-TAN) and Cefepime-Zidebactam (FEP-ZID or WCK-5222).
In this case, whole-genome sequencing of the organism was also done and has shown multiple mutations (in genes encoding PBP3, OprD, efflux pumps and AmpC) – the reason why it was extremely drug-resistant.
Not only was the organism hard to treat, its presence in lung-tissue and bone meant in-vitro tests meant little in actual treatment – as absorption rates of drugs in lungs and bone tissue is poor. A higher dosage owing to lower MIC of WCK-5222, enabled increased dosage initially and a lowered dosage there-on leading to a successful treatment in the patient.
This study wasn’t sponsored by Wockhardt as per the Funding section in the paper.
